GYRE (46) WVE (32) APMD (47) ANL (52) ⌘ Pro Terminal →

Design Therapeutics Inc. (DSGN) — RQD Stock Rating Cockpit

$11.06 -0.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Design Therapeutics Inc. (DSGN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $692.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DSGN)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

42.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

26.00>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE44% OF RANGE

L: $6$11.06H: $17

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on DSGN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-32.1% ROIC with 42.0% gross margin and -7.88% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 26.00 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

12/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like DSGN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DSGN)

✓Walkthrough of DSGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DSGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.68%📐 HORIZONTAL RANGE

2026-10-30O $10.96H $11.17L $10.51C $11.06VOL 249.5K

RES: $16.53SUP: $9.08SMA50: $12.66SMA200: $12.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DSGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DSGN Butterfly Map → + Track DSGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DSGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DSGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DSGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DSGN)

Health Care Rank #477 of 1016 ⚔️ GYRE vs DSGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DSGN vs. GYRE, WVE, APMD, ANL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Design Therapeutics Inc. (DSGN) ranks #477 by composite RQD confidence (45/100, grade D) and #401 by equity capitalization ($692.2M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with DSGN at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DSGN ACTIVE Design Therapeutics Inc.	D	45/100	—	—	-32.1%	-0.18%	$692.2M	Benchmark Subject
GYRE Gyre Therapeutics Inc.	D	46/100	72.3x	95.4%	25.4%	-9.59%	$714.8M	/gyre-vs-dsgn →
WVE Wave Life Sciences Inc.	E	32/100	—	—	-35.0%	-0.28%	$715.9M	/wve-vs-dsgn →
APMD Apnimed Inc.	D	47/100	—	—	—	-9.45%	$721.9M	/apmd-vs-dsgn →
ANL Adlai Nortye Group Ltd.	D+	52/100	—	—	—	+0.78%	$662.0M	/anl-vs-dsgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001807120

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Design Therapeutics Inc. (DSGN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$69.8M, operating cash flow of -$54.4M, and free cash flow of -$54.6M (-25.6% YoY). On the balance sheet, DSGN closed FY2025 with $226.2M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$69.8M	-$54.4M	-$54.6M	$226.2M	—
FY2024 (FY)	2024-12-31	$0	-$49.6M	-$43.1M	-$43.4M	$252.1M	—
FY2023 (FY)	2023-12-31	$0	-$66.9M	-$58.6M	-$58.6M	—	—

3. DSGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DSGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Design Therapeutics Inc. (NASDAQ: DSGN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $11.06 (-0.18% 1D, market cap $692.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DSGN ranks #477 in composite RQD confidence.

How does DSGN compare to GYRE and WVE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DSGN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.1%. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D grade (46/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M) and WVE (Wave Life Sciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DSGN?

Per DSGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001807120), Design Therapeutics Inc. generated $0 in revenue, -$69.8M in net income, and -$54.6M in free cash flow against $226.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DSGN trading relative to its 50-day, 200-day, and 52-week technical levels?

DSGN last traded at $11.06 (-0.18% on volume of 276,616 shares), positioning the stock -12.64% below its 50-day simple moving average ($12.66) and -9.12% below its 200-day simple moving average ($12.17). Across its 52-week range of $6.16 to $17.25, DSGN sits at the 44.2% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.68 to $12.44).

DSGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell DSGN stock right now?

Design Therapeutics Inc. (DSGN) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.

What is DSGN's 12-month price target and RQD AI Jury consensus?

DSGN's 12-month base price target is $10.41 (range $8.12 to $18.11), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: DSGN RQD Cockpit DSGN 12M Forecast DSGN Earnings & Move DSGN Dividends & DRIP DSGN Insiders & 13F DSGN Whale Options DSGN Profit Sankey DSGN News & Why